It wasn’t too many years ago when we were busy theorizing about the market opportunity for GLP-1 weight loss drugs. Now, the big question is the moneymaking potential for other peptides that might soon move to more regulated channels.
It wasn’t too many years ago when we were busy theorizing about the market opportunity for GLP-1 weight loss drugs. Now, the big question is …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Zara Stone, tech culture reporter at The San Francisco Standard, explains how startups are gearing up for potential FDA approval…
An FDA committee will meet next month to discuss lifting a ban on a number of peptides marketed for wellness. Compounding…
The compounds have exploded in popularity, but big questions about safety and effectiveness are still unresolved.
There is a version of this story that ends well.A class of molecules with genuine biological potential, freed from bureaucratic…
As peptides grow more mainstream, experts weigh in on sourcing, safety, transparency, telemedicine, and what consumers should…
Backed by a famous cricketer and valued at almost $500 million, Everlab wants to make preventative health mainstream. The science…
